References
- Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004). Stages in the development of Parkinson’s disease-related pathology. Cell and Tissue Research, 318(1), 121–134. https://doi.org/10.1007/s00441-004-0956-9
- Carman, L. S., Gage, F. H., & Shults, C. W. (1991). Partial lesion of the substantia nigra: Relation between extent of lesion and rotational behavior. Brain Research, 553(2), 275–283. https://doi.org/10.1016/0006-89939190835-j
- Chang, J. W., Wachtel, S. R., Young, D., & Kang, U. J. (1999). Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson’s disease: Studies on medial forebrain bundle and striatal lesions. Neuroscience, 88(2), 617–628. https://doi.org/10.1016/s0306-45229800217-6
- Chen, Z., Guan, Q., Cao, X., Xu, Y., Wang, L., & Sun, S. Effect of antisense FosB and CREB on the expression of prodynorphin gene in rats with levodopa-induced dyskinesias. (2006). Journal of Huazhong University of Science and Technology, 26(5), 542–544. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban. https://doi.org/10.1007/s11596-006-0514-7
- Dragašević-Mišković, N., Petrović, I., Stanković, I., & Kostić, V. S. (2019). Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients. Expert Opinion on Pharmacotherapy, 20(2), 219–230. https://doi.org/10.1080/14656566.2018.1543407
- Engeln, M., Bastide, M. F., Toulmé, E., Dehay, B., Bourdenx, M., Doudnikoff, E., Li, Q., Gross, C. E., Boué-Grabot, E., Pisani, A., Bezard, E., & Fernagut, P. O. (2016). Selective inactivation of striatal FosB/ΔFosB-Expressing neurons alleviates L-DOPA-induced dyskinesia. Biological Psychiatry, 79(5), 354–361. https://doi.org/10.1016/j.biopsych.2014.07.007
- Lee, C. S., Cenci, M. A., Schulzer, M., & Björklund, A. (2000). Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson’s disease. Brain: A Journal of Neurology, 123(Pt 7), 1365–1379. https://doi.org/10.1093/brain/123.7.1365
- LeWitt, P. A. (2015). Levodopa therapy for Parkinson’s disease: Pharmacokinetics and pharmacodynamics. Movement Disorders: Official Journal of the Movement Disorder Society, 30(1), 64–72. https://doi.org/10.1002/mds.26082
- Simola, N., Morelli, M., & Carta, A. R. (2007). The 6-hydroxydopamine model of Parkinson’s disease. Neurotoxicity Research, 11(3–4), 151–167. https://doi.org/10.1007/BF03033565
- Teng, L., Hong, F., He, J. C., Ren, X. X., & Yang, M. C. (2018). The effect of Compound Dihuang Formula on GSK3β signal transduction pathway on Parkinson’s disease model rats. Chinese Journal of Traditional Chinese Medicine, 36(04), 815–818. https://doi.org/10.13193/j.issn.1673-7717.2018.04.012
- Thanvi, B., Lo, N., & Robinson, T. (2007). Levodopa-induced dyskinesia in Parkinson’s disease: Clinical features, pathogenesis, prevention and treatment. Postgraduate Medical Journal, 83(980), 384–388. https://doi.org/10.1136/pgmj.2006.054759
- Ungerstedt, U. (1968). 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. European Journal of Pharmacology, 5(1), 107–110. https://doi.org/10.1016/0014-29996890164-7
- Vogel, E. W., 3rd, Panzer, M. B., Morales, F. N., Varghese, N., Bass, C. R., Meaney, D. F., & Morrison, B. (2020). Direct observation of low strain, high rate deformation of cultured brain tissue during primary blast. Annals of Biomedical Engineering, 48(4),1196–1206. 3rd. https://doi.org/10.1007/s10439-019-02437-4
- You, H., Mariani, L. L., Mangone, G., Le Febvre de Nailly, D., Charbonnier-Beaupel, F., & Corvol, J. C. (2018). Molecular basis of dopamine replacement therapy and its side effects in Parkinson’s disease. Cell and Tissue Research, 373(1), 111–135. https://doi.org/10.1007/s00441-018-2813-2